Combo immunotherapy produces distinct waves of cancer-fighting T cells
Md.Ayesha Sultana
Penn Medicine’s Abramson Cancer Center recently uncovered a significant insight into the workings of combination immunotherapy, revealing that each dose produces a unique, new wave of cancer-fighting T cells. This finding challenges the longstanding idea that combination immunotherapy, specifically the pairing of checkpoint inhibitors like anti-PD-1 and anti-CTLA-4, simply fortifies a stable population of T cells that steadily attacks the tumours over time. Instead, researchers found that each infusion of the therapy recruits a fresh batch of T cells, with distinct “clonal waves” that continuously renew the immune system’s attack on cancer cells.
This discovery holds particular significance for advanced melanoma patients, as the new waves of T cells appear to maintain a high level of effectiveness and resilience, counteracting the natural tendency of T cells to become “exhausted” after prolonged exposure to cancer cells. These “exhausted” cells, while still functional, lose some ability to fight the cancer effectively. By recruiting new waves of T cells with each dose, the combination therapy helps to sustain a dynamic and potent immune response throughout the treatment.
To capture these intricate patterns, Penn Medicine researchers developed an innovative tracking tool called Cyclone. This algorithm analyzes T cells by tracking their unique receptors over time, allowing scientists to follow each patient’s evolving immune response. By examining blood samples from melanoma patients across different treatment points, Cyclone provided researchers with a clearer understanding of how different populations of T cells emerged with each dose. The ability to track such changes offers not only a more precise view of how immunotherapy functions but also promises to help optimize future immunotherapies by tailoring treatments to maximize immune activity without over stimulating the immune system.
This study not only provides a new perspective on how checkpoint inhibitors can be used but also points the way toward more personalized approaches to immunotherapy in cancer treatment. By understanding the dynamic nature of T cell recruitment, future treatments could be designed to leverage these waves, helping the immune system to stay one step ahead of rapidly adapting tumours.
